Aida Doostkam, Kamyar Iravani, Leila Malekmakan, Ghazal Gholamabbas, Jamshid Roozbeh, Amir Soltaniesmaeili
Journal: Scientific reports 2024;14(1):17576
PMID: 39079962
Chronic kidney disease (CKD) is characterised by a progressive reduction in renal function. However, due to long-standing biochemical changes and the accumulation of waste products, many organs and systems are affected in CKD patients. This study aimed to investigate the protective effects and possible mechanisms of curcumin as a therapeutic agent on hearing impairment in patients with CKD. This research was a prospective double-blind placebo-controlled study. Participants were randomly divided into two study groups (n=20 in the experimental group and n=20 in the placebo group). Each participant in the experimental group received curcumin as one 500 mg capsule daily in the morning with food for 12 weeks. Results showed a statistically significant difference between participants receiving curcumin and those on a placebo. After 12 weeks, a daily dose of 500 mg of curcumin significantly improved hearing loss in CKD patients. Authors concluded that curcumin may be used as a therapeutic agent for treating hearing loss in patients with CKD. However, further research with a larger sample size is recommended.
Hearing impairment in patients with chronic kidney disease (CKD), can affect the quality of life. At present, hearing dysfunction does not have an approved pharmacologic therapy. This study aimed to investigate the protective effects and possible mechanisms of curcumin as a therapeutic agent on hearing impairment in patients with chronic kidney disease. We conducted a randomized controlled trial of 40 chronic kidney disease patients not on dialysis with hearing impairment. Participants were randomly divided into two groups. One group received curcumin daily and the other received a placebo for 12 weeks. The interval between III and V waves, latency of wave V, auditory brain stem response (ABR) threshold, speech reception threshold (SRT), and speech discrimination score (SDS) were evaluated and analyzed before and after the intervention. After treatment, in the curcumin group, III-V waves interval and the latency of wave V were significantly reduced (P value < 0.0001), also ABR threshold was demonstrated a significant improvement (P value < 0.0001). In the trial group, the SDS was increased (P = 0.001) and the SRT was attenuated (P < 0.0001). We had either significant deterioration due to the course of the disease or insignificant changes in the placebo group. Daily administration of curcumin, can significantly improve hearing impairment in CKD patients. Accordingly, curcumin should be considered as a therapeutic option for treating hearing impairment in patients with chronic kidney disease.
© 2024. The Author(s).
© Copyright 2026, Nutrition Evidence
NED wishes to thank the following organisations for their support:
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.